In our study; we aim to analyze the correlation between pre-treatment serum vitamin D (VD) levels and breast cancer prognostic features in newly diagnosed breast cancer patients presenting to our department.

Breast cancer is the most common cancer diagnosed in females in more and less developed regions, with more cases occurring in less developed (883,000 cases) than more developed regions (794,000). In Egypt, breast cancer is the commonest cancer in females representing about (38.8%) of cancers in females.

Decades of epidemiologic research have led to the identification of a number of lifestyle and environmental breast cancer risk factors, including menstrual and/or reproductive history, use of hormones, anthropometry, and alcohol consumption, each typically explaining a modest proportion of the variation in disease risk.

Vitamin D exists as vitamin D2 (Calciferol, the storage form) and D3 (Cholecalciferol, the active form), which are metabolized to 25-hydroxyvitamin D [25(OH)D], the major circulating vitamin D metabolite; Besides, its physiological functions, vitamin D levels have also been studied as a risk factor for several hormonal cancers including breast cancer (BC). Vitamin D is not technically a vitamin, ie, it is not an essential dietary factor; rather, it is a pro-hormone produced photo-chemically in the skin from 7-dehydrocholesterol. The molecular structure of vitamin D is closely allied to that of classic steroid hormones (eg, estradiol, cortisol, and aldosterone) in that they have the same root ring structure. Technically, vitamin D is a secosteroid.

The vitamin D receptor (VDR) is a member of the nuclear receptor superfamily and plays a central role in the biological actions of vitamin D. The vitamin D receptor regulates the expression of numerous genes involved in calcium/phosphate homeostasis, cellular proliferation and differentiation, and immune response, largely in a ligand-dependent manner. To understand the global function of the vitamin D system in physio-pathological processes, great effort has been devoted to the detection of the vitamin D receptor in various tissues and cells, many of which have been identified as vitamin D targets.

According to a 2010 analysis, the vitamin D receptor significantly affects 229 human genes. Many of these genes have long been associated with autoimmune diseases and cancers. Greater than 36 types of tissue have been identified as having a Vitamin D Receptor including the breast .

In a study by. plasma vitamin D levels were correlated with deoxyribonucleic acid (DNA) repair capacity levels in women with breast cancer.

In another study there was an association between vitamin D insufficiency or deficiency and tumors with worse prognostic features. Low vitamin D levels were shown to be a risk factor for estrogen receptor (ER) negative tumors, with positive axilla and a higher rate of cell proliferation in Brazilian postmenopausal women.

A study that evaluated serum vitamin D levels in female patients with recently identified benign or malignant lesions of the breast and its associations with tumor histology. Vitamin D was associated with tumor aggressiveness.

However, the effect of vitamin D deficiency on breast cancer prognosis and its role as a non-invasive bio-marker of breast cancer outcomes warrants further investigation.

Newly diagnosed non-metastatic breast cancer patients presenting to clinical oncology department, Assiut university Hospitals will be assessed for pre-treatment serum vitamin D levels (classified as sufficiency (30-100 ng/mL), insufficiency (20- <30 ng/mL) and deficiency (<20 ng/mL) through a blood sample obtained from the patient before receiving any type of treatments for their cancer and analyzed using enzyme-linked immunosorbent assay (ELISA) kit for vitamin D serum levels, patients characteristics (age, menopausal status, body mass index (BMI as weight in kilograms divided by squared height in meters (kg/m2), data on breast cancer (histopathological type, grade, tumor stage, lymph node status), hormone status (estrogen receptor (ER), progesterone receptor(PR)), human epidermal growth factor receptor type 2 (HER2) and epithelial proliferative activity described in percentage (Ki-67) will be obtained from patient file records . Time to tumor relapse whether locally or distant metastases and overall survival will be recorded. Correlation between these data and the pre-treatment vitamin D levels will be done.

• Definition of menopause: the permanent cessation of menses for 12 consecutive months in the absence of chemotherapy, tamoxifen, toremifine, or ovarian suppression and follicle-stimulating hormone (FSH) and estradiol levels in the postmenopausal range.
• Tumor grade defined according to the Nottingham (also called Elston-Ellis) modification of the Scarff-Bloom-Richardson grading system Grade 1 tumor (well-differentiated). Grade 2 tumor (moderately differentiated). Grade 3 tumor (poorly differentiated).
• Tumor stage will be classified according to American Joint Committee on Cancer (AJCC) staging manual eighth edition (2017).
• Definition of HER-2 positivity according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer: Testing criteria define HER2-positive status when (on observing within an area of tumor that amounts to >10% of contiguous and homogeneous tumor cells) there is evidence of protein overexpression (IHC) or gene amplification (HER2 copy number or HER2/CEP17 ratio by ISH based on counting at least 20 cells within the area). If results are equivocal (revised criteria), reflex testing should be performed using an alternative assay (IHC or ISH).

Inclusion Criteria:

• Female patients
• Newly diagnosed breast cancer patients.
• Histologically confirmed invasive breast carcinoma (IBC)
• Non- metastatic.
• Treatment naïve patients.
• Age: ≥18 and older
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
• Patients must have normal organ function as regards LFTs and RFTs

Exclusion Criteria:

• Male patients
• Metastatic patients
• Previous history of breast cancer diagnosis or treatment
• Kidney impairment or renal stones
• History of parathyroidectomy
• Hypercalcemia, defined as serum level >11 mg/dl.
• Abnormal laboratory data for: AST (SGOT), ALT (SGPT), Serum Bilirubin, Alkaline phosphatase, Creatinine and/or Creatinine clearance, and Albumin.
• Female patients who are pregnant or breast feeding.
• Patients already on treatment or previously treated for vitamin D defeciency

Female patients with newly diagnosed invasive breast cancer

Female patients newly diagnosed with non-metastatic breast cancer, treatment-naive presenting to clinical oncology department at Assiut University Hospitals